Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: Correlation with tumor angiogenesis

Digestive and Liver Disease

Volumn 42, Issue 1, 2010, Pages 20-27

  Cianchi, F ^a   Cuzzocrea, S ^b   Vinci, M C ^a   Messerini, L ^a   Comin, C E ^a   Navarra, G ^b   Perigli, G ^a   Centorrino, T ^b   Marzocco, S ^c   Lenzi, E ^a   Battisti, N ^a   Trallori, G ^a   Masini, E ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Invasive front; Microvessel density; Tumor invasion; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PROSTAGLANDIN E2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CAPILLARY DENSITY; COLORECTAL TUMOR; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; FEMALE; HUMAN; HUMAN TISSUE; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE LEVEL; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; UPREGULATION;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 73149108007     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.04.010     Document Type: Article

References (41)

1. Folkman J. Tumor angiogenesis. Adv Cancer Res 43 (1985) 175-203
2. Bikfalvi A. Significance of angiogenesis in tumor progression and metastasis. Eur J Cancer 31A (1995) 1101-1104
3. Blood C.H., and Zetter B.R. Tumor interaction with the vasculature: angiogenesis and tumor metastases. Biochim Biophys Acta 1032 (1990) 89-118
4. Uzzan B., Nicolas P., Cucherat M., and Perret G.Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64 (2004) 2941-2955
5. Frank R.E., Saclarides T.J., Leurgans S., Speziale N.J., Drab E.A., and Rubin D.B. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222 (1995) 696-699
6. Koukourakis M.I., Giatromanolaki A., Sivridis E., Gatter K.C., and Harris A.L. Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. Clin Cancer Res 11 (2005) 8653-8660
7. Polverini P.J., and Strieter R.M. Role of proangiogenic cytokines and inhibitors of neovascularization in tumor angiogenesis. In: Voest E.E., and D'Amore P.A. (Eds). Tumor angiogenesis and microcirculation (2001), Marcel Dekker, New York p. 265-84
8. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor-1. Cancer Res 63 (2005) 1138-1143
9. Giatromanolaki A., Sivridis E., and Koukourakis M.I. Tumor angiogenesis: vascular growth and survival. APMIS 112 (2004) 431-440
10. Gately S., and Li W.W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31 (2004) 2-11
11. Fukumura D., Kashiwagi S., and Jain R.K. The role of nitric oxide in tumour progression. Nat Rev Cancer 6 (2006 Jul) 521-534
12. Williams C.S., and DuBois R.N. Prostaglandin endoperoxide synthase: why two isoforms?. Am J Physiol 270 (1996) G393-400
13. Koki A.T., Leahy K.M., Harmon J.M., and Masferrer J.L. Cyclooxygenase-2 and cancer. In: Harris R.E. (Ed). COX-2 blockade in cancer prevention and therapy (2003), Humana Press, Totowa 185-203
14. Hendrickse C.W., Kelly R.W., Radley S., Donovan I.A., Keighley B., and Neoptolemos J.P. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 81 (1994) 1219-1223
15. Cianchi F., Cortesini C., Bechi P., Fantappiè O., Messerini L., Vannacci A., et al. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121 (2001) 1339-1347
16. Iniguez M.A., Rodriguez A., Volpert O.V., Fresno M., and Redondo J.M. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9 (2003) 73-78
17. Nathan C., and Xie Q.W. Nitric oxide synthase: roles, tolls, and controls. Cell 78 (1994) 915-918
18. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87 (1990) 1620-1624
19. Hofseth L.J., Hussain S.P., Wogan G.N., and Harris C.C. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 28 (2000) 1387-1404
20. Cianchi F., Cortesini C., Fantappiè O., Messerini L., Schiavone N., Vannacci A., et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 162 (2003) 793-801
21. Cianchi F., Cortesini C., Fantappiè O., Messerini L., Sardi I., Lasagna N., et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10 (2004) 2694-2704
22. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. American Joint Committee on cancer staging manual (2002), Springer, New York
23. Cianchi F., Cortesini C., Magnelli L., Fanti E., Papucci L., Schiavone N., et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 11 (2006) 2716-2726
24. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., et al. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84 (1992) 1875-1887
25. Pradelles P., Grassi J., and MacLouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 57 (1985) 1170-1175
26. Montes de Oca M., Loeb E., Torres S.H., De Sanctis J., Hernández N., and Tálamo C. Peripheral muscle alterations in non-COPD smokers. Chest 133 (2008) 13-18
27. Ueno H., Murphy J., Jass J.R., Mochizuki H., and Talbot I.C. Tumour "budding" as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40 (2002) 127-132
28. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
29. Fox S.B., Gatter K.C., Bicknell R., Going J.J., Stanton P., Coke T.G., et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53 (1993) 4161-4163
30. Zhang H., and Sun X.F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 97 (2002) 1037-1041
31. Tomozawa S., Tsuno N.H., Sunami E., Hatano K., Kitayama J., Osada T., et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83 (2000) 324-328
32. Prall F. Tumor budding in colorectal carcinoma. Histopathology 50 (2007) 151-162
33. Ueda J., Semba S., Chiba H., Sawada N., Seo Y., Kasuga M., et al. Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 74 (2007) 32-41
34. Higashiguchi T., Hotta T., Takifuji K., Yokoyama S., Matsuda K., Tominaga T., et al. Clinical impact of matrix metalloproteinase-7 mRNA expression in the invasive front and inner surface of tumor tissues in patients with colorectal cancer. Dis Colon Rectum 50 (2007) 1585-1593
35. Hlubek F., Brabletz T., Budczies J., Pfeiffer S., Jung A., and Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer 121 (2007) 1941-1948
36. Kobayashi H., Boelte K.C., and Lin P.C. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 14 (2007) 377-386
37. Roland C.L., Harken A.H., Sarr M.G., and Barnett C.C. ICAM-1 expression determines malignant potential of cancer. Surgery 141 (2007) 705-707
38. Giatromanolaki A., Koukourakis M.I., Sivridis E., O'Byrne K., Gatter K.C., and Harris A.L. Invading vs. inner" (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol 192 (2000) 140-149
39. Giatromanolaki A., Sivridis E., Simopoulos C., Polychronidis A., Gatter K.C., Harris A.L., et al. Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clin Exp Metastasis 19 (2002) 673-679
40. Giatromanolaki A., Sivridis E., Minopoulos G., Polychronidis A., Manolas C., Simopoulos C., et al. Differential assessment of vascular survival ability and tumor angiogenesis activity in colorectal cancer. Clin Cancer Res 8 (2002) 1185-1191
41. Koukourakis M.I., Giatromanolaki A., Thorpe P.E., Brekken R.A., Sivridis E., Kakolyris S., et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60 (2000) 3088-3095